Lataa...
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis
GIFT‐I is a phase 3 trial evaluating the efficacy and safety of a 12‐week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for treatment of Japanese hepatitis C virus genotype 1b–infected patients. It consists of a double‐blind, placebo‐controlled substudy of patients withou...
Tallennettuna:
| Julkaisussa: | Hepatology |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5049673/ https://ncbi.nlm.nih.gov/pubmed/26147154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27972 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|